<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195897</url>
  </required_header>
  <id_info>
    <org_study_id>2005-001-CHB</org_study_id>
    <nct_id>NCT00195897</nct_id>
  </id_info>
  <brief_title>Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)</brief_title>
  <official_title>Early Assessment of Anthracycline-induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's
      and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity,
      resulting in a marked left ventricular function impairment that may lead to heart failure.

      The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on
      cardiac function monitoring using echocardiography or radionuclide angiography. The aim of
      this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin
      and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline
      cardiotoxicity.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No patients; only 6 enrolled after 2 years
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">6</enrollment>
  <condition>Lymphoma</condition>
  <condition>Heart Failure, Congestive</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hodgkin lymphoma disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)

          -  Age &gt; 18 y/o and &lt; 70 y/o

          -  WHO score &lt; or = 2

          -  Life expectancy &gt; 6 mo

          -  Left ventricular ejection fraction &gt; 50%

          -  Informed consent

        Exclusion Criteria:

          -  Previous chemotherapy using anthracyclines

          -  History of radiation therapy

          -  History of congestive heart failure

          -  History of chronic renal insufficiency

          -  Contra indication to MR examination

          -  Atrial fibrillation and significant arrhythmia

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Manrique, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Jardin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002 May;13(5):710-5.</citation>
    <PMID>12075738</PMID>
  </reference>
  <reference>
    <citation>Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 Sep 24;339(13):900-5. Review.</citation>
    <PMID>9744975</PMID>
  </reference>
  <reference>
    <citation>Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104(4):158-63.</citation>
    <PMID>11279304</PMID>
  </reference>
  <reference>
    <citation>Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003 Mar-Apr;10(2):132-9.</citation>
    <PMID>12673177</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Anthracyclines</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Radionuclide</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Troponin</keyword>
  <keyword>Natriuretic Peptide, Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

